GlassScriptPhysician profile
Audrey J Woolrich
NPI 1598865297
$15,604.32
in general payments reported to CMS, 2019-2025
30 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $5,404 · 2021: $1,389 · 2022: $2,297 · 2023: $1,754 · 2024: $2,010 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,241 · Honoraria: $625 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,240.90 |
| Honoraria | $625.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $10,215.04 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,042.43 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $878.73 | 2019-2025 | Linzess, Creon |
| Ferring Pharmaceuticals INC. | $421.71 | 2019-2022 | |
| Ardelyx, INC. | $414.42 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $316.71 | 2019-2024 | Dificid |
| Boston Scientific Corporation | $295.84 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $295.31 | 2019-2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $284.20 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $222.43 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $148.88 | 2024-2025 | Dupixent |
| Alexion Pharmaceuticals, INC. | $134.54 | 2024 | |
| Genentech USA, INC. | $134.03 | 2024-2025 | Actemra |
| Lilly USA, LLC | $127.48 | 2020-2023 | Taltz |
| Kiniksa Pharmaceuticals International, Plc | $119.85 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $87.48 | 2019 | |
| Amgen INC. | $82.02 | 2020-2024 | Krystexxa |
| Pfizer INC. | $65.12 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $48.77 | 2025 | Lupkynis |
| Janssen Biotech, INC. | $48.23 | 2020-2024 | Tremfya |
| Ucb, INC. | $32.89 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $28.17 | 2025 | |
| Radius Health, INC. | $25.45 | 2025 | Binosto, Tymlos |
| Redhill Biopharma INC. | $25.00 | 2024 | Talicia |
| Astrazeneca Pharmaceuticals LP | $23.19 | 2025 | Saphnelo |
| Exact Sciences Corporation | $20.80 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $18.70 | 2023 | Arcalyst |
| Shire North American Group INC | $18.43 | 2019 | |
| Capsovision, INC. | $15.06 | 2024 | Capsocam Plus |
| Endo Pharmaceuticals INC. | $13.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Woolrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.